CA2807507A1 - Treatment of mitochondrial diseases with naphthoquinones - Google Patents

Treatment of mitochondrial diseases with naphthoquinones Download PDF

Info

Publication number
CA2807507A1
CA2807507A1 CA2807507A CA2807507A CA2807507A1 CA 2807507 A1 CA2807507 A1 CA 2807507A1 CA 2807507 A CA2807507 A CA 2807507A CA 2807507 A CA2807507 A CA 2807507A CA 2807507 A1 CA2807507 A1 CA 2807507A1
Authority
CA
Canada
Prior art keywords
alkyl
levels
dione
hydrogen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2807507A
Other languages
English (en)
French (fr)
Inventor
Orion D. Jankowski
Andrew W. Hinman
Guy M. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioelectron Technology Corp
Original Assignee
Edison Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Phamaceuticals Inc filed Critical Edison Phamaceuticals Inc
Publication of CA2807507A1 publication Critical patent/CA2807507A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2807507A 2010-08-06 2011-08-04 Treatment of mitochondrial diseases with naphthoquinones Abandoned CA2807507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40104410P 2010-08-06 2010-08-06
US61/401,044 2010-08-06
PCT/US2011/046630 WO2012019029A2 (en) 2010-08-06 2011-08-04 Treatment of mitochondrial diseases with naphthoquinones

Publications (1)

Publication Number Publication Date
CA2807507A1 true CA2807507A1 (en) 2012-02-09

Family

ID=45560075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2807507A Abandoned CA2807507A1 (en) 2010-08-06 2011-08-04 Treatment of mitochondrial diseases with naphthoquinones

Country Status (10)

Country Link
US (1) US20130345312A1 (enExample)
EP (1) EP2600857A4 (enExample)
JP (2) JP6045494B2 (enExample)
AU (1) AU2011285619B2 (enExample)
BR (1) BR112013002877A2 (enExample)
CA (1) CA2807507A1 (enExample)
EA (1) EA201300215A1 (enExample)
MX (1) MX2013001469A (enExample)
SG (1) SG187744A1 (enExample)
WO (1) WO2012019029A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583087C (en) 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
HUE033304T2 (en) 2005-06-01 2017-11-28 Bioelectron Tech Corp Redoxactive therapeutic agents for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
US8716527B2 (en) 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP3827815B1 (en) 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
DK2424495T3 (en) 2009-04-28 2018-04-30 Bioelectron Tech Corp TREATMENT OF LEVERS HEREDIC OPTICAL NEUROPATHY AND DOMINANT OPTICAL ATROPHY WITH TOCOTRIENOL QUINONES
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
EP2734512B1 (en) 2011-07-19 2019-11-20 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
PL2872497T5 (pl) 2012-07-12 2020-02-28 Khondrion Ip B.V. Pochodne chromanylowe do leczenia choroby mitochondrialnej
CA2883882A1 (en) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
EP2961420B1 (en) 2013-03-01 2019-09-11 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CN105517533A (zh) * 2013-03-01 2016-04-20 康德生物医疗技术公司 治疗线粒体疾病的方法
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
HK1220451A1 (zh) 2013-03-15 2017-05-05 Bioelectron Technology Corporation 用於治疗氧化应激障碍的烷基-杂芳基取代醌衍生物
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
SG10202003299PA (en) 2014-12-16 2020-05-28 Ptc Therapeutics Inc Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
ES3033538T3 (en) 2015-10-08 2025-08-05 Khondrion Ip B V Novel compounds for treating mitochondrial disease
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
MX391378B (es) 2015-12-17 2025-03-21 Ptc Therapeutics Inc Derivados de fluoroalquil-, fluoroalcoxi-, fenoxi-, heteroariloxi-, alcoxi- y amina-1,4-benzoquinona para tratamiento de trastornos de estres oxidativo.
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
MX2019011692A (es) 2017-04-05 2020-02-10 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales.
CA3056810A1 (en) 2017-04-21 2018-10-25 University Of Tasmania Therapeutic compounds and methods
KR20210071949A (ko) * 2018-07-29 2021-06-16 무스크 파운데이션 포 리서치 디벨롭먼트 신경학적 질환 또는 미트콘드리아 질환 치료용 화합물
JP7586815B2 (ja) 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン
CA3127654A1 (en) 2019-01-25 2020-07-30 Universitat Autonoma De Barcelona Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases
IL291898A (en) 2019-10-04 2022-06-01 Stealth Biotherapeutics Inc Quinone-, hydroquinone- and naphthoquinone-analogues of vatiquinone for treatment of mitochondrial disorder diseases
CN120554211A (zh) 2020-04-03 2025-08-29 康德生物医疗有限公司 用于预防和/或治疗线粒体疾病的组合物和方法
IT202100006065A1 (it) * 2021-03-15 2022-09-15 Univ Degli Studi Padova Composto per l’uso nel metodo di trattamento delle malattie mitocondriali da disfunzione dei complessi i, ii, iii della catena respiratoria
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
JP2003226639A (ja) * 2002-01-31 2003-08-12 Hisamitsu Pharmaceut Co Inc 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
HUE033304T2 (en) * 2005-06-01 2017-11-28 Bioelectron Tech Corp Redoxactive therapeutic agents for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
KR20080047959A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
US8716527B2 (en) * 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
EP3827815B1 (en) * 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EA201200977A1 (ru) * 2009-12-31 2013-01-30 Эдисон Фармасьютикалз, Инк. Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
EP2601168A4 (en) * 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
WO2012170773A1 (en) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones

Also Published As

Publication number Publication date
JP2016041772A (ja) 2016-03-31
AU2011285619B2 (en) 2016-12-01
SG187744A1 (en) 2013-03-28
EP2600857A4 (en) 2014-06-11
BR112013002877A2 (pt) 2016-05-31
WO2012019029A2 (en) 2012-02-09
US20130345312A1 (en) 2013-12-26
MX2013001469A (es) 2013-05-14
AU2011285619A1 (en) 2013-03-07
EP2600857A2 (en) 2013-06-12
JP2013541502A (ja) 2013-11-14
EA201300215A1 (ru) 2013-07-30
WO2012019029A3 (en) 2013-08-15
JP6045494B2 (ja) 2016-12-14

Similar Documents

Publication Publication Date Title
AU2011285619B2 (en) Treatment of mitochondrial diseases with naphthoquinones
US20140031432A1 (en) Treatment of mitochondrial diseases with vitamin k
US9464016B2 (en) Catechol derivatives for treatment of oxidative stress diseases
EP2564843B1 (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9296712B2 (en) Resorufin derivatives for treatment of oxidative stress disorders
US7432305B2 (en) Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9868711B2 (en) Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
WO2012170773A1 (en) Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
US20170209393A1 (en) Benzoquinone derivatives for treating oxidative stress disorders
US20140275045A1 (en) Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
HK1182941A (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1108651B (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1173364A (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1124552A1 (en) Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
HK1173364B (en) Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
HK1124552B (en) Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170804